Reprogramming CAR-T cell function through synthetic cytokine receptors suppresses metastatic progression of TNBC
Patient T cells modified with chimeric antigen receptors (CARs) have shown remarkable therapeutic success in previously incurable cancers. However, despite its success in hematological malignancies, CAR-T therapy has shown only modest efficacy in solid tumors. The medical field has focused on developing new molecular designs that enhance CAR-T persistence, prevent exhaustion in the tumor microenvironment (TME), and increase the specificity of the CAR-T cell to various tumor antigens. However, much less effort has been placed on enhancing CAR-T cells' invasion into and migration through the stromal matrix of the TME, where they can elicit tumor-directed cytotoxicity. Here, we engineered CAR-T cells with synthetic cytokine receptors targeting inflammatory cytokines produced by the cells themselves, which increase their speed through collagen I matrices. We show that this enhanced motility is driven by increased CAR-T cell translocation through confined microchannels via cellular deformation, together with elevated migratory speeds in proximity to neighboring cells, suggesting improved responsiveness to local cues. These migration-enhanced CAR-T cells significantly reduce both primary tumor size and distant organ metastasis in triple-negative breast cancer (TNBC) mouse models compared to standard CAR-T cells. These results support molecular design strategies that exploit mechanisms to improve cellular therapies for metastatic solid tumors.